These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 1982973)
1. Evidence that lack of brain dopamine during development can increase the susceptibility for aggression and self-injurious behavior by influencing D1-dopamine receptor function. Breese GR; Criswell HE; Mueller RA Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14 Suppl():S65-80. PubMed ID: 1982973 [TBL] [Abstract][Full Text] [Related]
2. Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: relevance to Lesch-Nyhan disease. Breese GR; Mueller RA; Napier TC; Duncan GE Adv Exp Med Biol; 1986; 204():197-215. PubMed ID: 2947429 [No Abstract] [Full Text] [Related]
3. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors. Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972 [TBL] [Abstract][Full Text] [Related]
4. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior. Sivam SP Brain Res; 1989 Oct; 500(1-2):119-30. PubMed ID: 2481560 [TBL] [Abstract][Full Text] [Related]
5. A dopamine deficiency model of Lesch-Nyhan disease--the neonatal-6-OHDA-lesioned rat. Breese GR; Criswell HE; Duncan GE; Mueller RA Brain Res Bull; 1990 Sep; 25(3):477-84. PubMed ID: 2127238 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity. Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257 [TBL] [Abstract][Full Text] [Related]
7. Monkeys with unilateral ventromedial tegmental lesions of the brain stem: models for Parkinson's disease and Lesch-Nyhan syndrome. Goldstein M Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):311-8. PubMed ID: 2501825 [TBL] [Abstract][Full Text] [Related]
8. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767 [TBL] [Abstract][Full Text] [Related]
9. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists. Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320 [TBL] [Abstract][Full Text] [Related]
10. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses. Weick BG; Walters JR Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219 [TBL] [Abstract][Full Text] [Related]
11. Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors. Criswell HE; Mueller RA; Breese GR Neuropsychopharmacology; 1992 Sep; 7(2):95-103. PubMed ID: 1418306 [TBL] [Abstract][Full Text] [Related]
12. Dopamine D1 antagonists potentiate the durations of bar and cling catalepsy and the dorsal immobility response in rats. Meyer ME; Cottrell GA; Van Hartesveldt C Pharmacol Biochem Behav; 1992 Mar; 41(3):507-10. PubMed ID: 1533938 [TBL] [Abstract][Full Text] [Related]
13. Lesch-Nyhan syndrome and its variants: examining the behavioral and neurocognitive phenotype. Harris JC Curr Opin Psychiatry; 2018 Mar; 31(2):96-102. PubMed ID: 29227296 [TBL] [Abstract][Full Text] [Related]
14. Dopamine agonist induced self-mutilative biting behavior in monkeys with unilateral ventromedial tegmental lesions of the brainstem: possible pharmacological model for Lesch-Nyhan syndrome. Goldstein M; Kuga S; Kusano N; Meller E; Dancis J; Schwarcz R Brain Res; 1986 Mar; 367(1-2):114-20. PubMed ID: 2938664 [TBL] [Abstract][Full Text] [Related]
15. Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Kostrzewa RM; Gong L Pharmacol Biochem Behav; 1991 Jul; 39(3):677-82. PubMed ID: 1686103 [TBL] [Abstract][Full Text] [Related]
16. A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease. Khasnavis T; Reiner G; Sommerfeld B; Nyhan WL; Chipkin R; Jinnah HA Mol Genet Metab; 2016 Apr; 117(4):401-6. PubMed ID: 26922636 [TBL] [Abstract][Full Text] [Related]
17. Relationship of dopamine to serotonin in the neonatal 6-OHDA rat model of Lesch-Nyhan syndrome. Allen SM; Davis WM Behav Pharmacol; 1999 Sep; 10(5):467-74. PubMed ID: 10780253 [TBL] [Abstract][Full Text] [Related]
18. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development. Neal BS; Joyce JN Brain Res Dev Brain Res; 1991 Jun; 60(2):105-13. PubMed ID: 1832593 [TBL] [Abstract][Full Text] [Related]
19. Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome. Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Mueller RA Pharmacol Biochem Behav; 1984 Sep; 21(3):459-61. PubMed ID: 6436840 [TBL] [Abstract][Full Text] [Related]